684249-45-4

Basic information

• Product Name: 4-(4-iodophenoxy)piperidine
• Synonyms: 4-(4-iodophenoxy)piperidine
• CAS NO: 684249-45-4
• Molecular Weight: 303.143
• Mol File: 684249-45-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 4-(4-iodophenoxy)piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-iodophenoxy)piperidine(684249-45-4)
• EPA Substance Registry System: 4-(4-iodophenoxy)piperidine(684249-45-4)

Safety Data

• Hazardous Substances Data: 684249-45-4(Hazardous Substances Data)

Upstream product

• 540-38-5 p-Iodophenol 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 352-34-1 4-fluoro-1-iodobenzene 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 346617-98-9 1,1-dimethylethyl 4-[(4-iodophenyl)oxy]-1-piperidinecarboxylate 

Downstream Products

• 684249-46-5 4-[(4-iodophenyl)oxy]-1-(1-methylethyl)piperidine 
• 1373010-41-3 1-isopropyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine 
• 1430471-90-1 2-(dimethylamino)-1-(4-(4-iodophenoxy)piperidin-1-yl)ethanone 
• 1430471-96-7 2-(dimethylamino)-1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidin-1-yl)ethanone 

Relevant articles and documents

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

PLK-4 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The invention is directed to a compound represented by the following Structural Formula (I) and (II) and pharmaceutically acceptable salts thereof: (Formula (I)); (Formula (IV)). Compounds represented by this structural formula are kinase inhibitors and are, therefore, disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

4- (4-(HETEROCYCLYLALKOXY}PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER’S

The present invention provides, in a first aspect, a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein: R1 represents -C1-6 alkyl-O-C1-6 alkyl, -C3-8 cycloalkyl, aryl, heterocyclyl, heteroaryl and other groups; X represents a bond, O, CO, OCH2, CH2O or SO2; Z represents CO, CONR10 or SO2; R10 represents hydrogen, C1-6 alkyl, -C3-8 cycloalkyl, aryl, heterocyclyl, heteroaryl; A represents a single or a double bond; m and n independently represent 0, 1 or 2; R2 represents hydrogen, C1-6 alkyl or C1-6 alkoxy; R3 represents halogen, C1-6 alkyl, hydroxy, C1-6 alkoxy, cyano, amino, -COC1-6 alkyl, -SO2C1-6 alkyl or trifluoromethyl; R4 represents -(CH2)q-NR11R12 or a group of formula (i) wherein all the other substituents are as defined in claim 1. Compounds of formula (I) and their pharmaceutically acceptable salts have affinity for and are antagonists and/or inverse agonists of the histamine H3 receptor and are believed to be of potential use in the treatment of neurological diseases including Alzheimer's disease.